Druvith/medqa1 huggingface dataset:
Question:  what research (or clinical trials) is being done for Wilms Tumor and Other Childhood Kidney Tumors ?
Answer: New types of treatment are being tested in clinical trials.
                    Information about clinical trials is available from the NCI website.     Targeted therapy     Targeted therapy is a treatment that uses drugs or other substances to identify and attack specific cancer cells without harming normal cells. Targeted therapy used to treat childhood kidney tumors may include the following:            -  Monoclonal antibodies: This targeted therapy uses antibodies made in the laboratory, from a single type of immune system cell. These antibodies can identify substances on cancer cells or normal substances that may help cancer cells grow. The antibodies attach to the substances and kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Lorvotuzumab is being studied in the treatment of recurrent Wilms tumor.     -  Kinase inhibitors: This targeted therapy blocks signals that cancer cells need to grow and divide. LOXO-101 and entrectinib are kinase inhibitors being studied to treat congenital mesoblastic nephroma.     -  Histone methyltransferase inhibitors: This targeted therapy slows down the cancer cell's ability to grow and divide. Tazemetostat is being studied in the treatment of rhabdoid tumor of the kidney.
                
                
                    Patients may want to think about taking part in a clinical trial.
                    For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.   Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.   Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
                
                
                    Patients can enter clinical trials before, during, or after starting their cancer treatment.
                    Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.   Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials.
Question:  What is (are) Mycosis Fungoides and the Szary Syndrome ?
Answer: Key Points
                    - Mycosis fungoides and the Szary syndrome are diseases in which lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin.    - Mycosis fungoides and the Szary syndrome are types of cutaneous T-cell lymphoma.     - A sign of mycosis fungoides is a red rash on the skin.    - In the Szary syndrome, cancerous T-cells are found in the blood.    - Tests that examine the skin and blood are used to detect (find) and diagnose mycosis fungoides and the Szary syndrome.    - Certain factors affect prognosis (chance of recovery) and treatment options.
                
                
                    Mycosis fungoides and the Szary syndrome are diseases in which lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin.
                    Normally, the bone marrow makes blood stem cells (immature cells) that become mature blood stem cells over time. A blood stem cell may become a myeloid stem cell or a lymphoid stem cell. A myeloid stem cell becomes a red blood cell, white blood cell, or platelet. A lymphoid stem cell becomes a lymphoblast and then one of three types of lymphocytes (white blood cells):         -  B-cell lymphocytes that make antibodies to help fight infection.    -  T-cell lymphocytes that help B-lymphocytes make the antibodies that help fight infection.    -  Natural killer cells that attack cancer cells and viruses.         In mycosis fungoides, T-cell lymphocytes become cancerous and affect the skin. In the Szary syndrome, cancerous T-cell lymphocytes affect the skin and are in the blood.
                
                
                    Mycosis fungoides and the Szary syndrome are types of cutaneous T-cell lymphoma.
                    Mycosis fungoides and the Szary syndrome are the two most common types of cutaneous T-cell lymphoma (a type of non-Hodgkin lymphoma). For information about other types of skin cancer or non-Hodgkin lymphoma, see the following PDQ summaries:         -  Adult Non-Hodgkin Lymphoma Treatment     -  Skin Cancer Treatment     -  Melanoma Treatment     -  Kaposi Sarcoma Treatment
                
              
                
                    In the Szary syndrome, cancerous T-cells are found in the blood.
                    Also, skin all over the body is reddened, itchy, peeling, and painful. There may also be patches, plaques, or tumors on the skin. It is not known if the Szary syndrome is an advanced form of mycosis fungoides or a separate disease.
Question:  What are the symptoms of Mycosis Fungoides and the Szary Syndrome ?
Answer: A sign of mycosis fungoides is a red rash on the skin. Mycosis fungoides may go through the following phases:         -  Premycotic phase: A scaly, red rash in areas of the body that usually are not exposed to the sun. This rash does not cause symptoms and may last for months or years. It is hard to diagnose the rash as mycosis fungoides during this phase.    -  Patch phase: Thin, reddened, eczema -like rash.    -  Plaque phase: Small raised bumps (papules) or hardened lesions on the skin, which may be reddened.     -  Tumor phase: Tumors form on the skin. These tumors may develop ulcers and the skin may get infected.        Check with your doctor if you have any of these signs.
Question:  How to diagnose Mycosis Fungoides and the Szary Syndrome ?
Answer: Tests that examine the skin and blood are used to detect (find) and diagnose mycosis fungoides and the Szary syndrome. The following tests and procedures may be used:         -   Physical exam and history : An exam of the body to check general signs of health, including checking for signs of disease, such as lumps, the number and type of skin lesions, or anything else that seems unusual. Pictures of the skin and a history of the patients health habits and past illnesses and treatments will also be taken.    -   Complete blood count with differential : A procedure in which a sample of blood is drawn and checked for the following:                - The number of red blood cells and platelets.      - The number and type of white blood cells.      - The amount of hemoglobin (the protein that carries oxygen) in the red blood cells.       - The portion of the blood sample made up of red blood cells.              -   Peripheral blood smear : A procedure in which a sample of blood is viewed under a microscope to count different circulating blood cells (red blood cells, white blood cells, platelets, etc.) and see whether the cells look normal.     -  Skin biopsy : The removal of cells or tissues so they can be viewed under a microscope to check for signs of cancer. The doctor may remove a growth from the skin, which will be examined by a pathologist. More than one skin biopsy may be needed to diagnose mycosis fungoides.    -   Immunophenotyping : A process used to identify cells, based on the types of antigens or markers on the surface of the cell. This process may include special staining of the blood cells. It is used to diagnose specific types of leukemia and lymphoma by comparing the cancer cells to normal cells of the immune system.    -  T-cell receptor (TCR) gene rearrangement test: A laboratory test in which cells in a sample of tissue are checked to see if there is a certain change in the genes. This gene change can lead to too many of one kind of T-cells (white blood cells that fight infection) to be made.    -   Flow cytometry : A laboratory test that measures the number of cells in a sample of blood, the percentage of live cells in a sample, and certain characteristics of cells, such as size, shape, and the presence of tumor markers on the cell surface. The cells are stained with a light-sensitive dye, placed in a fluid, and passed in a stream before a laser or other type of light. The measurements are based on how the light-sensitive dye reacts to the light.
Question:  What is the outlook for Mycosis Fungoides and the Szary Syndrome ?
Answer: Certain factors affect prognosis (chance of recovery) and treatment options. The prognosis (chance of recovery) and treatment options depend on the following:          - The stage of the cancer.    - The type of lesion (patches, plaques, or tumors).        Mycosis fungoides and the Szary syndrome are hard to cure. Treatment is usually palliative, to relieve symptoms and improve the quality of life. Patients with early stage disease may live many years.
Question:  what research (or clinical trials) is being done for Mycosis Fungoides and the Szary Syndrome ?
Answer: Patients may want to think about taking part in a clinical trial.
                    For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.   Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.   Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
                
                
                    Patients can enter clinical trials before, during, or after starting their cancer treatment.
                    Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.   Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials.
Question:  What is (are) Colorectal Cancer ?
Answer: Key Points
                    - Colorectal cancer is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum.     - Colorectal cancer is the second leading cause of death from cancer in the United States.     - Different factors increase or decrease the risk of getting colorectal cancer.
                
                
                    Colorectal cancer is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum.
                    The colon and rectum are parts of the body's digestive system. The digestive system removes and processes nutrients (vitamins, minerals, carbohydrates, fats, proteins, and water) from foods and helps pass waste material out of the body. The digestive system is made up of the mouth, throat, esophagus, stomach, and the small and large intestines. The colon (large bowel) is the first part of the large intestine and is about 5 feet long. Together, the rectum and anal canal make up the last part of the large intestine and are 6-8 inches long. The anal canal ends at the anus (the opening of the large intestine to the outside of the body).      Cancer that begins in the colon is called colon cancer, and cancer that begins in the rectum is called rectal cancer. Cancer that begins in either of these organs may also be called colorectal cancer.   See the following PDQ summaries for more information about colorectal cancer:         -   Colorectal Cancer Prevention     -  Colon Cancer Treatment     -  Rectal Cancer Treatment     -  Genetics of Colorectal Cancer
                
                
                    Colorectal cancer is the second leading cause of death from cancer in the United States.
                    The number of new colorectal cancer cases and the number of deaths from colorectal cancer are decreasing a little bit each year. But in adults younger than 50 years, there has been a small increase in the number of new cases each year since 1998. Colorectal cancer is found more often in men than in women.
Question:  Who is at risk for Colorectal Cancer? ?
Answer: Different factors increase or decrease the risk of getting colorectal cancer. Anything that increases your chance of getting a disease is called a risk factor. Anything that decreases your chance of getting a disease is called a protective factor.   For information about risk factors and protective factors for colorectal cancer, see the PDQ summary on Colorectal Cancer Prevention.
Question:  What is (are) Juvenile Myelomonocytic Leukemia ?
Answer: Key Points
                    - Juvenile myelomonocytic leukemia is a childhood disease in which too many myelocytes and monocytes (immature white blood cells) are made in the bone marrow.    - Signs and symptoms of juvenile myelomonocytic leukemia include fever, weight loss, and feeling very tired.    - Certain factors affect prognosis (chance of recovery) and treatment options.
                
                
                    Juvenile myelomonocytic leukemia is a childhood disease in which too many myelocytes and monocytes (immature white blood cells) are made in the bone marrow.
                    Juvenile myelomonocytic leukemia (JMML) is a rare childhood cancer that occurs more often in children younger than 2 years. Children who have neurofibromatosis type 1 and males have an increased risk of juvenile myelomonocytic leukemia.    In JMML, the body tells too many blood stem cells to become two types of white blood cells called myelocytes and monocytes. Some of these blood stem cells never become mature white blood cells. These immature white blood cells are called blasts. Over time, the myelocytes, monocytes, and blasts crowd out the red blood cells and platelets in the bone marrow. When this happens, infection, anemia, or easy bleeding may occur.
Question:  What are the symptoms of Juvenile Myelomonocytic Leukemia ?
Answer: Signs and symptoms of juvenile myelomonocytic leukemia include fever, weight loss, and feeling very tired. These and other signs and symptoms may be caused by JMML or by other conditions. Check with your doctor if you have any of the following:         -  Fever for no known reason.    - Having infections, such as bronchitis or tonsillitis.    - Feeling very tired.    - Easy bruising or bleeding.    - Skin rash.    - Painless swelling of the lymph nodes in the neck, underarm, stomach, or groin.    - Pain or a feeling of fullness below the ribs.
Question:  What is the outlook for Juvenile Myelomonocytic Leukemia ?
Answer: Certain factors affect prognosis (chance of recovery) and treatment options. The prognosis (chance of recovery) and treatment options for JMML depend on the following:         - The age of the child at diagnosis.    - The number of platelets in the blood.    - The amount of a certain type of hemoglobin in red blood cells.
Question:  What are the treatments for Juvenile Myelomonocytic Leukemia ?
Answer: Treatment of juvenile myelomonocytic leukemia (JMML) may include the following:         -  Combination chemotherapy.    -  Stem cell transplant.    -  13-cis-retinoic acid therapy.    - A clinical trial of a new treatment, such as targeted therapy.        Check the list of NCI-supported cancer clinical trials that are now accepting patients with juvenile myelomonocytic leukemia. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your doctor about clinical trials that may be right for you. General information about clinical trials is available from the NCI website.
Question:  What is (are) Primary CNS Lymphoma ?
Answer: Key Points
                    - Primary central nervous system (CNS) lymphoma is a disease in which malignant (cancer) cells form in the lymph tissue of the brain and/or spinal cord.    - Having a weakened immune system may increase the risk of developing primary CNS lymphoma.     - Tests that examine the eyes, brain, and spinal cord are used to detect (find) and diagnose primary CNS lymphoma.    - Certain factors affect prognosis (chance of recovery) and treatment options.
                
                
                    Primary central nervous system (CNS) lymphoma is a disease in which malignant (cancer) cells form in the lymph tissue of the brain and/or spinal cord.
                    Lymphoma is a disease in which malignant (cancer) cells form in the lymph system. The lymph system is part of the immune system and is made up of the lymph, lymph vessels, lymph nodes, spleen, thymus, tonsils, and bone marrow. Lymphocytes (carried in the lymph) travel in and out of the central nervous system (CNS). It is thought that some of these lymphocytes become malignant and cause lymphoma to form in the CNS. Primary CNS lymphoma can start in the brain, spinal cord, or meninges (the layers that form the outer covering of the brain). Because the eye is so close to the brain, primary CNS lymphoma can also start in the eye (called ocular lymphoma).
Question:  Who is at risk for Primary CNS Lymphoma? ?
Answer: Having a weakened immune system may increase the risk of developing primary CNS lymphoma. Anything that increases your chance of getting a disease is called a risk factor. Having a risk factor does not mean that you will get cancer; not having risk factors doesnt mean that you will not get cancer. Talk with your doctor if you think you may be at risk.    Primary CNS lymphoma may occur in patients who have acquired immunodeficiency syndrome (AIDS) or other disorders of the immune system or who have had a kidney transplant. For more information about lymphoma in patients with AIDS, see the PDQ summary on AIDS-Related Lymphoma Treatment.
Question:  What is the outlook for Primary CNS Lymphoma ?
Answer: Certain factors affect prognosis (chance of recovery) and treatment options. The prognosis (chance of recovery) depends on the following:         - The patient's age and general health.     - The level of certain substances in the blood and cerebrospinal fluid (CSF).    - Where the tumor is in the central nervous system, eye, or both.    - Whether the patient has AIDS.         Treatment options depend on the following:          - The stage of the cancer.    - Where the tumor is in the central nervous system.    - The patient's age and general health.    - Whether the cancer has just been diagnosed or has recurred (come back).        Treatment of primary CNS lymphoma works best when the tumor has not spread outside the cerebrum (the largest part of the brain) and the patient is younger than 60 years, able to carry out most daily activities, and does not have AIDS or other diseases that weaken the immune system.
Question:  What is (are) Ovarian Germ Cell Tumors ?
Answer: Key Points
                    - Ovarian germ cell tumor is a disease in which malignant (cancer) cells form in the germ (egg) cells of the ovary.     - Signs of ovarian germ cell tumor are swelling of the abdomen or vaginal bleeding after menopause.     - Tests that examine the ovaries, pelvic area, blood, and ovarian tissue are used to detect (find) and diagnose ovarian germ cell tumor.     - Certain factors affect prognosis (chance of recovery and treatment options).
                
                
                    Ovarian germ cell tumor is a disease in which malignant (cancer) cells form in the germ (egg) cells of the ovary.
                    Germ cell tumors begin in the reproductive cells (egg or sperm) of the body. Ovarian germ cell tumors usually occur in teenage girls or young women and most often affect just one ovary.    The ovaries are a pair of organs in the female reproductive system. They are in the pelvis, one on each side of the uterus (the hollow, pear-shaped organ where a fetus grows). Each ovary is about the size and shape of an almond. The ovaries make eggs and female hormones.      Ovarian germ cell tumor is a general name that is used to describe several different types of cancer. The most common ovarian germ cell tumor is called dysgerminoma. See the following PDQ summaries for information about other types of ovarian tumors:          -  Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment     -  Ovarian Low Malignant Potential Tumors Treatment
Question:  What are the symptoms of Ovarian Germ Cell Tumors ?
Answer: Signs of ovarian germ cell tumor are swelling of the abdomen or vaginal bleeding after menopause. Ovarian germ cell tumors can be hard to diagnose (find) early. Often there are no symptoms in the early stages, but tumors may be found during regular gynecologic exams (checkups). Check with your doctor if you have either of the following:          - Swollen abdomen without weight gain in other parts of the body.     - Bleeding from the vagina after menopause (when you are no longer having menstrual periods).